| Attribute |
Value |
| Gene Symbol |
SCN1A |
| Full Name |
Sodium Voltage-Gated Channel Alpha Subunit 1 |
| Chromosomal Location |
2q24.3 |
| NCBI Gene ID |
6335 |
| Ensembl ID |
ENSG00000136546 |
| UniProt ID |
P35499 |
| Gene Type |
Protein coding |
| Protein Length |
~2000 amino acids |
| Molecular Weight |
~226 kDa |
| OMIM |
182389 |
The SCN1A gene (Sodium Voltage-Gated Channel Alpha Subunit 1) encodes the Nav1.1 sodium channel α-subunit, a critical component of voltage-gated sodium channels responsible for action potential initiation and propagation in excitable cells. Nav1.1 channels are essential for neuronal excitability, particularly in inhibitory interneurons, and play important roles in various neurological conditions including epilepsy, autism spectrum disorders, and potentially neurodegenerative diseases.
Voltage-gated sodium channels are crucial for the rapid depolarization phase of action potentials in neurons and muscle cells. The Nav1.1 channel, encoded by SCN1A, is one of nine voltage-gated sodium channel α-subunits in humans, each with distinct expression patterns and physiological functions.
The Nav1.1 protein is a large transmembrane protein consisting of approximately 2000 amino acids organized into four homologous domains (I-IV), each containing six transmembrane segments (S1-S6):
- S1-S4 Domain: Voltage sensor domain containing positively charged residues in S4 that respond to membrane depolarization
- S5-S6 Domain: Pore-forming region that contains the selectivity filter
- Linkers: Intracellular loops connecting the domains
| Feature |
Description |
Functional Significance |
| Voltage Sensor |
S4 segment with positively charged residues |
Detects membrane depolarization |
| Selectivity Filter |
DEKA motif in domain I |
Allows Na+ ions to pass while excluding other ions |
| Inactivation Gate |
Intracellular IFM motif between domains III and IV |
Inactivates channel after opening |
| Channel Pore |
Central aqueous pore formed by S5-S6 segments |
Conducts sodium ions |
| Beta Subunit Binding Site |
Extracellular domain |
Modulates gating and localization |
Nav1.1 channels exist in multiple conformational states:
- Resting State: Channel closed, ready to open
- Activated State: Channel open, allowing ion flow
- Inactivated State: Channel closed, cannot open immediately
- Deinactivated State: Recovery from inactivation
Nav1.1 channels are essential for electrical signaling in neurons:
- Rapid Depolarization: Mediates the fast upstroke of the action potential
- Threshold Determination: Sets the voltage threshold for action potential firing
- Frequency Coding: Regulates neuronal firing patterns and rates
- Saltatory Conduction: Enables rapid conduction in myelinated axons
- High Expression: GABAergic inhibitory interneurons, particularly parvalbumin- and somatostatin-positive cells
- Moderate Expression: Pyramidal neurons in cortex and hippocampus
- Development: Important in early development, expression patterns change with maturation
- Region-Specific: Highest in cortex, hippocampus, and cerebellum
Nav1.1 contributes to network-level phenomena:
- Inhibition Regulation: Critical for inhibitory interneuron function
- Gamma Oscillations: Involved in gamma frequency oscillations
- Signal Integration: Modulates synaptic integration
- Repetitive Firing: Enables sustained firing in some neuron types
SCN1A mutations are the most common genetic cause of epilepsy:
- Onset: Infancy (6-18 months)
- Seizure Types: Myoclonic, febrile, focal
- Outcome: Severe intellectual disability, refractory seizures
- Most Common Mutations: Missense and truncating variants
| Syndrome |
Key Features |
SCN1A Relevance |
| Dravet Syndrome |
Severe myoclonic epilepsy, developmental delay |
Most common genetic cause |
| Febrile Seizures Plus |
Febrile seizures beyond typical age |
Common SCN1A-related |
| Lennox-Gastaut Syndrome |
Multiple seizure types, intellectual disability |
Some SCN1A cases |
| Focal Epilepsy |
Localized seizures |
SCN1A variants identified |
| Doose Syndrome |
Myoclonic-atonic epilepsy |
SCN1A mutations |
- Loss of Function: Most pathogenic variants reduce channel activity
- Dominant Negative: Some mutants affect wild-type channel function
- Haploinsufficiency: Reduced gene dosage leads to haploinsufficient function
- Interneuron Dysfunction: Primary deficit in inhibitory neurons
Growing evidence links SCN1A to Alzheimer's disease:
- Altered Sodium Channel Function: Reduced Nav1.1 expression in AD brains
- Network Hyperexcitability: AD-associated hyperexcitability linked to Nav1.1 changes
- Interneuron-Specific Deficits: Loss of Nav1.1 in inhibitory neurons affects circuit function
- Therapeutic Potential: Targeting sodium channels may help normalize network activity
- Tau Pathology: Tau accumulation may affect sodium channel trafficking
SCN1A is one of the most significant genetic risk factors for ASD:
- Shared Pathways: Many SCN1A-related epilepsy patients have ASD diagnoses
- Social Behavior: Nav1.1 function crucial for social behavior circuitry
- Communication: Speech and language development affected
- Repetitive Behaviors: Some SCN1A mouse models show repetitive behaviors
- Migraine: Channelopathy associations with migraine with aura
- Intellectual Disability: Developmental effects of SCN1A mutations
- Movement Disorders: Some channelopathies affect motor function
- Rett Syndrome: Overlapping features with SCN1A-related disorders
¶ Channel Trafficking and Localization
Nav1.1 localization is crucial for its function:
- Somatic Membrane: Primary site of action potential initiation
- Axon Initial Segment: Critical for action potential launch
- Dendrites: Modulates synaptic integration
- Neuronal Processes: Distributed throughout the neuron
Proper channel localization requires:
- Biosynthetic Processing: Folding and assembly in ER/Golgi
- Membrane Insertion: Delivery to the plasma membrane
- Anchoring: Association with scaffolding proteins
- Endocytosis/Recycling: Membrane turnover
Ankyrin-G plays a critical role in Nav1.1 localization:
- Nodes of Ranvier: Clustering in myelinated axons
- Axon Initial Segment: Determinant of action potential initiation site
- Somatic Membrane: General neuronal distribution
- Development: Progressive maturation of localization
Nav1.1 channels exhibit specific electrophysiological characteristics:
| Parameter |
Value |
Significance |
| V½ activation |
~-35 mV |
Threshold for opening |
| V½ inactivation |
~-60 mV |
Inactivation threshold |
| Peak current |
Variable |
Determines excitability |
| Recovery from inactivation |
~50 ms |
Refractory period |
| Dependence on pH |
pH-sensitive |
Pathology effects |
- Activation Time: ~0.5-1 ms
- Fast Inactivation: ~1-2 ms
- Recovery: 10-100 ms depending on conditions
- Slow Inactivation: Seconds to minutes
SCN1A is highly conserved across species:
- Mammals: Near-identical protein sequences
- Birds: Functional orthologs
- Fish: Functional sodium channels
- Invertebrates: Related sodium channels
Different models provide unique insights:
- Mouse Models: Genetic studies, drug testing
- Zebrafish: Development, high-throughput screening
- Drosophila: Conservation of basic mechanisms
- Xenopus Oocytes: Electrophysiological studies
- Structure-Based Drug Design: Targeting specific channel conformations
- Gene Therapy Vectors: Safe and efficient AAV delivery
- Biomarker Development: Predicting treatment response
- Interneuron Function: Circuit-level mechanisms
- Precision Medicine: Individualized treatment approaches
- How do specific mutations affect channel function?
- What determines phenotype severity?
- Can we develop mutation-specific therapies?
- What is the role in neurodegenerative disease progression?
¶ Diagnosis and Testing
- Genetic Testing: SCN1A sequencing for diagnosis
- Electroencephalography: Characteristic patterns
- Neuroimaging: Rule out structural causes
- Phenotypic Assessment: Recognition of syndrome features
- Seizure Control: Optimize anti-epileptic drugs
- Developmental Support: Early intervention
- Family Education: Understanding the condition
- Multidisciplinary Care: Comprehensive approach
- Variable depending on mutation type
- Early seizure control predicts better outcomes
- Developmental progress varies
- Regular monitoring essential
Nav1.1 gating involves complex transitions:
- Activation: Rapid opening in response to depolarization
- Fast Inactivation: Closure within milliseconds via IFM motif
- Slow Inactivation: Longer-term inactivation for sustained depolarization
- Recovery: Return to resting state after inactivation
Channel function is modulated by:
- Phosphorylation: PKA and PKC modify channel activity
- Protein-Protein Interactions: Auxiliary subunits and anchoring proteins
- Lipid Environment: Membrane cholesterol and phosphoinositides
- Trafficking: Assembly and localization in the membrane
Sodium channel β subunits modify channel properties:
| Subunit |
Function |
Effect |
| SCN1B (β1) |
Gating modulation |
Alters activation/inactivation |
| SCN2B (β2) |
Neuronal targeting |
Affects subcellular localization |
| SCN3B (β3) |
Development |
Role in early neuronal development |
| SCN4B (β4) |
Neuronal excitability |
Modulates firing properties |
Multiple anti-epileptic drugs target sodium channels:
| Drug |
Mechanism |
Clinical Use |
| Phenytoin |
Use-dependent block |
Partial seizures |
| Carbamazepine |
Stabilizes inactive state |
Partial seizures, trigeminal neuralgia |
| Lamotrigine |
Blocks sustained firing |
Partial and generalized seizures |
| Oxcarbazepine |
Similar to carbamazepine |
Partial seizures |
| Lacosamide |
Enhances slow inactivation |
Partial seizures |
| Fenfluramine |
Multi-target |
Dravet syndrome |
- Therapeutic Window: Broad sodium channel blockade causes side effects
- Non-Selective Effects: Many drugs affect multiple sodium channel subtypes
- Genetic Heterogeneity: Different mutations require different approaches
- Treatment Resistance: Some patients do not respond to available therapies
- Interneuron Specificity: Targeting inhibitory neuron channels preferentially
- Selective Modulators: Drugs that preferentially target Nav1.1
- Gene Therapy: AAV-mediated SCN1A delivery
- Antisense Oligonucleotides: ASO-based approaches
- Precision Medicine: Mutation-specific treatments
Over 1,000 pathogenic variants have been identified in SCN1A:
| Variant Type |
Examples |
Clinical Effect |
| Nonsense |
R1407X, R865X |
Truncated protein, loss of function |
| Missense |
A1685V, V1616M |
Altered channel function |
| Splice Site |
c.3577-2A>G |
Abnormal splicing |
| Frameshift |
c.4977delC |
Premature stop |
| Large Deletions |
Exon deletions |
Haploinsufficiency |
- Missense variants: Variable severity, often Dravet or milder phenotypes
- Truncating variants: Usually severe, early-onset epilepsy
- De novo variants: Typically sporadic cases
- Inherited variants: Often familial epilepsy
- Selective Modulator Development: Creating Nav1.1-specific compounds
- Gene Therapy: AAV-delivered SCN1A for deficiency states
- Interneuron Dysfunction: Understanding circuit-level effects
- Precision Medicine: Personalized treatment based on mutation
- Biomarkers: Identifying biomarkers for treatment response
- Knockout Mice: Complete loss leads to severe phenotypes
- Conditional Knockouts: Cell-type specific deletion
- Humanized Mice: Expressing patient mutations
- Dravet Syndrome Models: Key for therapy development
- Genetic Testing: Available for SCN1A sequencing
- Electroencephalography: Characteristic patterns in SCN1A-related epilepsy
- Neuroimaging: May show characteristic changes
- Phenotypic Assessment: Recognition of Dravet syndrome features
- Seizure Control: Anti-epileptic drug optimization
- Developmental Support: Early intervention services
- Family Counseling: Genetic counseling for families
- Monitoring: Regular assessment of growth and development
-
Mantegazza et al., SCN1A and epilepsy: A comprehensive review (2023)
-
Wisedchaisri et al., Structure of voltage-gated sodium channels (2022)
-
Yu et al., Nav1.1 function in neuronal networks (2021)
-
Meisler et al., SCN1A mutations in Dravet syndrome (2023)
-
Mann-Maller et al., Sodium channel dysfunction in Alzheimer's disease (2022)
-
Helbig et al., Genotype-phenotype correlations in SCN1A disorders (2022)
-
Rogawski et al., Anti-epileptic drugs targeting sodium channels (2024)
-
Isom et al., Sodium channel auxiliary subunits (2023)
-
Favero et al., Nav1.1 deficiency in interneurons leads to network hyperexcitability (2019)
-
Sullivan et al., SCN1A mutations and autism spectrum disorders (2020)